Document is current
Any future updates will be listed below
-
Authors
Suárez‐Calvet, Marc https://orcid.org/0000-0002-2993-569X
Karikari, Thomas K
Ashton, Nicholas J https://orcid.org/0000-0002-6353-9316
Lantero Rodríguez, Juan
Milà‐Alomà, Marta
Gispert, Juan Domingo
Salvadó, Gemma
Minguillon, Carolina
Fauria, Karine
Shekari, Mahnaz
Grau‐Rivera, Oriol
Arenaza‐Urquijo, Eider M
Sala‐Vila, Aleix
Sánchez‐Benavides, Gonzalo
González‐de‐Echávarri, José Maria
Kollmorgen, Gwendlyn
Stoops, Erik
Vanmechelen, Eugeen
Zetterberg, Henrik
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Molinuevo, José Luis https://orcid.org/0000-0003-0485-6001
,
Beteta, Annabella
Cacciaglia, Raffaele
Cañas, Alba
Deulofeu, Carme
Cumplido, Irene
Dominguez, Ruth
Emilio, Maria
Falcon, Carles
Fuentes, Sherezade
Hernandez, Laura
Huesa, Gema
Huguet, Jordi
Marne, Paula
Menchón, Tania
Operto, Grégory
Polo, Albina
Pradas, Sandra
Soteras, Anna
Vilanova, Marc
Vilor‐Tejedor, Natalia
-
Funding
Funding for this research was provided by:
“la Caixa” Foundation (LCF/PR/GN17/50300004)
Alzheimer's Association (TriBEKa‐17‐519007)
H2020 Marie Skłodowska-Curie Actions (752310)
BrightFocus Foundation (A2020812F)
H2020 European Research Council (681712)
EU Joint Programme – Neurodegenerative Disease Research (JPND2019‐466‐236)
Instituto de Salud Carlos III (PI19/00155)
Instituto de Salud Carlos III (CP II 17/00029)
Ministerio de Ciencia, Innovación y Universidades (IJC2018‐037478‐I)
Ministerio de Ciencia, Innovación y Universidades (FJCI‐2017‐33437)
Ministerio de Ciencia, Innovación y Universidades (RYC2018‐026053‐I)
Ministerio de Economía y Competitividad (RYC‐2013‐13054)
Ministerio de Economía y Competitividad (IEDI‐2016‐00690)
Svenska Forskningsrådet Formas (2018‐02532)
Svenska Forskningsrådet Formas (2017‐00915)
Alzheimer's Drug Discovery Foundation (201809‐2016862)
Alzheimer's Drug Discovery Foundation (RDAPB‐201809‐2016615)
- License Information
-
More Information
Article History
Received: 11 June 2020
Revised: 9 September 2020
Accepted: 9 September 2020
First Online: 10 November 2020
Conflict of interest
: JDG has given lectures in symposia sponsored by the following for‐profit companies: General Electric, Philips and Biogen. GK is a full‐time employee of Roche Diagnostics GmbH. ES is an employee and EVM is a co‐founder of ADx NeuroSciences. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures‐based platform company at the University of Gothenburg. JLM has served/serves as a consultant or at advisory boards for the following for‐profit companies, or has given lectures in symposia sponsored by the following for‐profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences. The remaining authors declare that they have no conflict of interest.
